Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00866840 · ClinicalTrials.gov registry record · Phase 2
Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Phase 2 study, sponsored by Rutgers, The State University of New Jersey.
- Completed
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT00866840 is a Phase 2 study that has completed, run by Rutgers, The State University of New Jersey. The registered enrollment target is 13 participants.
The verdict
NCT00866840, a Phase 2 study, has completed, sponsored by Rutgers, The State University of New Jersey.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
RATIONALE: Riluzole may stop or slow the growth of tumor cells and may be an effective treatment for melanoma. PURPOSE: This phase II trial is studying how well riluzole works in treating patients with stage III or stage IV melanoma that cannot be removed by surgery.
Interventions
- DRUG riluzole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2009-04 |
| Est. Completion | 2013-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00866840
The ClinicalTrials.gov registry entry for NCT00866840 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rutgers, The State University of New Jersey, which has 413 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which riluzole is the first listed.
NCT00866840 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00866840 about?
NCT00866840 is a clinical study titled "Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery". RATIONALE: Riluzole may stop or slow the growth of tumor cells and may be an effective treatment for melanoma. PURPOSE: This phase II trial is studying how well riluzole works in treating patients with stage III or stage IV melanoma that cannot be removed by surgery.
What is the current status of trial NCT00866840?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2009-04. Estimated completion is 2013-07.
What interventions are being tested in trial NCT00866840?
The interventions under investigation include: riluzole (DRUG).
Who is sponsoring clinical trial NCT00866840?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.